Windtree Therapeutics Inc (WINT)

Windtree Therapeutics Inc is a biotechnology company listed on OTC Markets under the ticker WINT. The company focuses on developing therapies for acute cardiovascular diseases and related conditions. Its lead candidate, istaroxime, is in Phase 2b testing for acute decompensated heart failure and early cardiogenic shock. Windtree is also advancing AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials for respiratory distress syndrome in premature infants, along with Surfaxin for respiratory disease, Rostafuroxin for genetically associated hypertension, and oral and intravenous SERCA2a activators in preclinical development for chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor for cutaneous malignancies and solid tumors. The company has entered into strategic alliances and licensing agreements with several partners, including Laboratorios del Dr. Esteve, Lee’s Pharmaceutical, Zhaoke Pharmaceutical, Philip Morris USA, Johnson & Johnson, and Battelle Memorial Institute. Founded in 1992 and headquartered in Warrington, Pennsylvania, the company was formerly known as Discovery Laboratories, Inc., changing its name in April 2016.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.